10mcg dose selected to advance into Part B of Phase 1/2a study of VBI-1901 in recurrent GBM Expanded data from Part A of the Phase 1/2a study of VBI-1901 selected for poster presentation at ASCO Conference call and webcast Thursday,...
Read More
VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, is pleased to announce the appointment of Vlad Popovic, M.D., as Vice President, Clinical Development and Medical Affairs, reporting into Francisco Diaz-Mitoma, M.D.,...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the appointment of Joanne Cordeiro to its Board of Directors. Ms. Cordeiro most recently served as Chief Human Resources Officer and Executive...
Read More
Poster presentation to highlight data from three previously-conducted clinical studies of Sci-B-Vac®, VBI’s prophylactic Hepatitis B vaccine In all three studies, seroprotection rates of more than 98% were achieved after two vaccinations of Sci-B-Vac® VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”) (“the...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that David Anderson, Ph.D., Chief Scientific Officer, will present the poster, “CMV gB/pp65 eVLPs Formulated with GM-CSF as a Therapeutic Vaccine...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that Nell Beattie, Chief Business Officer, will present at the Oppenheimer 29th Annual Healthcare Conference on Wednesday, March 20, 2019 at 9:10 AM...
Read More
Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019 Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the study License and Collaboration with Brii Biosciences, to develop a functional cure...
Read More
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the study without modification Enrollment is complete in the high-dose study arm of Part A Expanded immunologic data and 6-month survival data from all three dose cohorts in Part...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the appointment of Blaine McKee, Ph.D., Executive Vice President and Chief Business Officer of ImmunoGen, Inc., to the company’s Board of...
Read More
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced its plans for a Phase 2 clinical study evaluating VBI-1501, the company’s prophylactic cytomegalovirus (CMV) vaccine candidate, following positive discussions with Health...
Read More